ClinicalTrials.gg
CompletedNCT06563856Updated Aug 21, 2024

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

A Phase 1 interventional study of TEPEZZA and EDP in Bioavailability and Bioequivalence, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2021, 5 years 5 months ago, and no results have been posted to the registry.
  • Registered 3 years 10 months after the study started (first participant enrolled Sep 2020, registered Aug 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing teprotumumab in Graves Ophthalmopathy — 2 open to participants now, 3 under way, 1 of them phase 3. teprotumumab · Graves Ophthalmopathy.

Enrollment
10th of 12
37 · median 56
Started
2020
the only one that year
Phase 1
4 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
10 of 12
Amgen

Among the 12 studies testing teprotumumab in Graves Ophthalmopathy, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 1, and was the 8th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

2 of the 12 studies testing teprotumumab in Graves Ophthalmopathy are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teprotumumab

teprotumumab: first FDA approval 2020 (TEPEZZA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing teprotumumab in Graves Ophthalmopathy, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.

03

Conditions studied

  • Bioavailability
  • Bioequivalence

Browse trials for

Keywords

  • Thyroid eye disease
  • Graves' ophthalmopathy
  • Graves' orbitopathy
  • Thyroid-associated ophthalmopathy
  • Immunology
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is able to provide written .
  • The participant is male or female 18 to 55 years of age, inclusive.
  • The participant has a (BMI) between 21 to 30 kg/m\^², inclusive, and a minimum weight of 55 kg at Screening.
  • The participant is considered by the investigator or designee to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead (ECG) results, and physical examination findings at Screening.
  • The participant has adequate venous access and can receive IV therapy.
  • Female participants of must have a negative serum pregnancy test at Screening and Check-in and negative urine pregnancy tests at all other protocol-specified time points. Participants who are sexually active with a non-vasectomized male partner must agree to use 2 reliable forms of during the study, one of which is recommended to be hormonal, such as an oral contraceptive.
  • Female participants must agree not to donate an egg/oocyte from Day 1 until 180 days after receiving the study drug.

Male participants must agree not to donate sperm from Day 1 until 180 days after receiving the study drug.

-The participant is willing and able to comply with all protocol requirements and evaluations for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • The participant has a positive test result for surface antigen, virus (HCV) antibody, or (HIV) types 1 or 2 antibodies at Screening.
  • The participant has a diagnosis of an disease; or a history of HIV, hepatitis B virus (HBV), or HCV infection; a history of inflammatory bowel disease (IBD), or a history of or active thyroid eye disease (TED) at Screening.
  • The participant has active liver disease or hepatic dysfunction at Screening or Check-in, as determined by (ALT) or aspartate aminotransferase (AST) levels >1.5 times (ULN).
  • The participant has (HbA1c) levels ≥8% and/or fasting glucose levels (after at least an 8-hour fast) >126 mg/dL (>7 mmol/L) at Screening.
  • The participant has a seated resting blood pressure of \<90/40 mmHg or >140/90 mmHg, or a seated pulse rate of \<40 beats per minute (bpm) or >99 bpm or is considered at Screening. One additional measurement can be taken if blood pressure and pulse rate are outside the specified limits.
  • The participant has clinically significant 12-lead abnormalities at Screening and Check-in or, in the opinion of the investigator, has a second- or third-degree atrioventricular (AV) block, or has any of the following:

QRS >120 msec

corrected for heart rate using Fridericia's formula (QTcF) >450 msec (males) or >470 msec (females)

PR interval >220 msec

  • The participant has used any prescription (excluding hormonal ) or over-the-counter medications (except paracetamol [up to 2 g per day]), including herbal or nutritional supplements, within 14 days before receiving the study drug.
  • The participant has a medical condition associated with an increased risk of bleeding - including a history of hematological diseases such as acquired disorders; coagulation disorders - including drug-induced thrombocytopenia, idiopathic thrombocytopenia, or von Willebrand's Disease; or requires the use of antiplatelet or anticoagulant medication.
  • Female participants who are lactating or planning to become pregnant from Screening through 180 days after receiving the study drug.
  • Male participants who are planning to impregnate a female partner from Day 1 through 180 days after receiving the study drug.
  • The participant has consumed alcohol-, caffeine-, or xanthine-containing products within 48 hours before the dose of study drug.
  • The participant is a smoker or has used nicotine or nicotine-containing products (e.g., snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 3 months before receiving the study drug.
  • The participant has a history of alcohol abuse or drug addiction within the past 6 months prior to Day 1 dosing.
  • The participant has a positive test result for drugs of abuse, alcohol, or cotinine (indicating active current smoking) at Screening or before receiving the study drug.
  • The participant is involved in strenuous activity or contact sports within 24 hours before receiving the study drug and during the study.
  • The participant has donated blood, had significant blood loss, or received a transfusion of any blood or blood products within 60 days prior to Day 1 dosing or received a plasma donation within 7 days prior to Day 1 dosing.
  • The participant has a history of relevant drug and/or food allergies (i.e., allergy or idiosyncratic reaction to components of TEPEZZA or ; prior reactions to mAbs, EDP, or excipients; or any significant food allergy that could preclude a standard diet in the clinical unit).
  • The participant participated in another study within 30 days (or 5 half-lives of the study drug, whichever is longer) prior to dosing on Day 1. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the date of Day 1 of the current study.
  • The participant has previously participated in a TEPEZZA investigational study or has received TEPEZZA or rHuPH20-containing products.
  • The participant has received a COVID-19 vaccination within 6 weeks before receiving the study drug or during the study.
  • The participant has a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Note: Testing will be performed according to site procedures.
  • The participant is mentally or legally incapacitated or has significant emotional problems at Screening or is expected to have them during the conduct of the study.
  • The participant has a history or presence of a clinically significant medical or psychiatric condition or disease in the opinion of the investigator or designee.
  • The participant had a history of any illness that, in the opinion of the investigator or designee, might confound the results of the study or pose an additional risk to the participant by participation in the study.
  • In the opinion of the investigator or designee, the participant is not suitable for entry into the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Cohort 1: TEPEZZA Dose A SubQ

    Participants will receive Dose A of TEPEZZA administered SubQ.

    Drug: TEPEZZA

  • Experimental
    Cohort 2: TEPEZZA Dose B SubQ

    Participants will receive Dose B of TEPEZZA administered SubQ.

    Drug: TEPEZZA

  • Experimental
    Cohort 3: TEPEZZA Dose B Intravenously (IV)

    Participants will receive Dose B of TEPEZZA administered IV.

    Drug: TEPEZZA

  • Experimental
    Cohort 4: TEPEZZA Dose B and EDP SubQ

    Participants will receive coadministered doses of TEPEZZA Dose B and EDP SubQ.

    Drug: TEPEZZA · Drug: EDP

Interventions

  • Administered as a SubQ injection or IV injection.

    Also known as: HZN-001

  • DrugEDP

    Administered as a SubQ injection.

06

What researchers measure

Primary outcomes

  1. Cohort 1, 2, and 4: Area Under the Serum Concentration-time Curve (AUC) From Time 0 Extrapolated to Infinity (AUCinf) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  2. Cohort 1, 2, and 4: AUC From Time 0 to the Last Quantifiable Concentration (AUClast) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  3. Cohort 1, 2, and 4: Percentage of the Area Extrapolated for Calculation of AUCinf (%AUCextrap) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  4. Cohort 1, 2, and 4: Maximum Observed Serum Concentration (Cmax) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  5. Cohort 1, 2, and 4: Last Quantifiable Serum Concentration (Clast) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  6. Cohort 1, 2, and 4: Time to Maximum Observed Serum Concentration (Tmax) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  7. Cohort 1, 2, and 4: Time of Last Quantifiable Serum Concentration (Tlast) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  8. Cohort 1, 2, and 4: Apparent Terminal Elimination Rate Constant (λz) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  9. Cohort 1, 2, and 4: Apparent Terminal Half-life (t1/2) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  10. Cohort 1, 2, and 4: Apparent Serum Clearance (CL/F) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  11. Cohort 1, 2, and 4: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

Secondary outcomes

  1. Cohort 3: AUCinf of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  2. Cohort 3: AUClast of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  3. Cohort 3: %AUCextrap of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  4. Cohort 3: Cmax of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  5. Cohort 3: Clast of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  6. Cohort 3: Tlast of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  7. Cohort 3: λz of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  8. Cohort 3: t1/2 of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  9. Cohort 3: Total Serum Clearance (CL) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  10. Cohort 3: Estimated Volume of Distribution at Steady State (Vss) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  11. Cohort 3: Volume of Distribution During the Terminal Phase (Vz) of TEPEZZA

    Time frame: Day 1 pre-dose to Day 71

  12. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Participants will be instructed to contact the investigator at any time after receiving the study drug, if any symptoms develop. A TEAE is defined as any event not present before exposure to study drug or any event already present that worsens in intensity or frequency after exposure.

    Time frame: Up to approximately Day 71

  13. Number of Participants Experiencing Serious Adverse Events (SAEs)

    An AE is considered an SAE if, in the view of either the investigator or sponsor, it results in any of the following outcomes: * Death * Life-threatening AE * Inpatient hospitalization or prolongation of existing hospitalization * Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions * Congenital anomaly or birth defect.

    Time frame: Up to approximately Day 71

  14. Number of Participants with Detectable Anti-drug Antibodies (ADA) to TAPEZZA

    Time frame: Day 1 pre-dose to Day 71

07

Study locations

1 site
  • PPD Development
    Las Vegas, Nevada 89113, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in May 2021, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 21, 2024
StartActual
Sep 22, 2020
Primary completionActual
May 27, 2021
CompletionActual
May 27, 2021
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06563856
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Sep 22, 2020
Primary completion
May 27, 2021
Completion
May 27, 2021
Last update
Aug 21, 2024

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teprotumumab

Start the discussion